MX2011011735A - Compounds and methods for inhibition of renin, and indications therefor. - Google Patents

Compounds and methods for inhibition of renin, and indications therefor.

Info

Publication number
MX2011011735A
MX2011011735A MX2011011735A MX2011011735A MX2011011735A MX 2011011735 A MX2011011735 A MX 2011011735A MX 2011011735 A MX2011011735 A MX 2011011735A MX 2011011735 A MX2011011735 A MX 2011011735A MX 2011011735 A MX2011011735 A MX 2011011735A
Authority
MX
Mexico
Prior art keywords
compounds
renin
methods
inhibition
indications therefor
Prior art date
Application number
MX2011011735A
Other languages
Spanish (es)
Inventor
Dean R Artis
Prabha N Ibrahim
Chao Zhang
Guoxian Wu
Yong Zhou
Shumeye Mamo
Samuel J Gillette
Yong-Liang Zhu
Jinyu Liu
Kam Zhang
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MX2011011735A publication Critical patent/MX2011011735A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds active as inhibitors of renin (e.g., compounds of Formula I) are described, as well as methods of using such compounds to treat diseases and conditions associated with the renin-angiotensin system. Formula (I).
MX2011011735A 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor. MX2011011735A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17541709P 2009-05-04 2009-05-04
PCT/US2010/033385 WO2010129467A1 (en) 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor

Publications (1)

Publication Number Publication Date
MX2011011735A true MX2011011735A (en) 2011-11-29

Family

ID=42237224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011735A MX2011011735A (en) 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor.

Country Status (5)

Country Link
CA (1) CA2761009A1 (en)
IL (1) IL216107A0 (en)
MX (1) MX2011011735A (en)
SG (1) SG175877A1 (en)
WO (1) WO2010129467A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP5627574B2 (en) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド Compounds and methods for treating inflammatory and fibrotic diseases
RU2012125070A (en) 2009-11-18 2013-12-27 Плексксикон, Инк. COMPOUNDS AND METHODS OF KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
RU2012131373A (en) 2009-12-23 2014-01-27 Плексксикон, Инк. COMPOUNDS AND METHODS OF KINASE MODULATION, AND ALSO INDICATIONS FOR SUCH MODULATION
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
TWI619713B (en) 2010-04-21 2018-04-01 普雷辛肯公司 Compounds and methods for kinase modulation, and indications therefor
PT2672967T (en) 2011-02-07 2018-12-07 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2012158957A2 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
CN102993094B (en) * 2011-09-08 2014-07-23 中国石油大学(北京) Synthesizing method of tetrahydroquinoline derivative
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
UY34893A (en) 2012-07-10 2014-02-28 Takeda Pharmaceutical DERIVATIVES OF AZAINDOL
WO2014039714A2 (en) 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
WO2014100620A2 (en) 2012-12-21 2014-06-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
MX2015012456A (en) 2013-03-15 2016-02-03 Plexxikon Inc Heterocyclic compounds and uses thereof.
JP6067181B2 (en) 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Aldosterone synthase inhibitor
CN105228983A (en) 2013-05-30 2016-01-06 普莱希科公司 The compound regulated for kinases and indication thereof
BR112016008276B1 (en) 2013-10-25 2021-03-02 Novartis Ag ring-fused bicyclic pyridyl derivatives, their uses and their intermediate, and pharmaceutical composition
RS62301B1 (en) 2013-12-20 2021-09-30 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102373700B1 (en) 2014-04-02 2022-03-11 인터뮨, 인크. Anti-fibrotic pyridinones
JP6832846B2 (en) 2014-09-15 2021-02-24 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Heterocyclic compounds and their uses
JP6585167B2 (en) 2014-10-03 2019-10-02 ノバルティス アーゲー Use of fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG10201912386RA (en) 2015-09-21 2020-02-27 Plexxikon Inc Heterocyclic compounds and uses thereof
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6921846B6 (en) 2016-03-16 2021-09-15 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for kinase regulation and its indications
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
EP3558991A2 (en) 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
JP2020511467A (en) 2017-03-20 2020-04-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． 4- (1- (1,1-di (pyridin-2-yl) ethyl) -6- (3,5-dimethylisoxazol-4-yl) -1H-pyrrolo [3,2- that inhibits the bromodomain b] Pyridin-3-yl) benzoic acid crystalline form
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
KR102615829B1 (en) 2017-07-25 2023-12-20 플렉시콘 인코퍼레이티드 Preparations of compounds that modulate kinases
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
CN112119072A (en) 2018-03-20 2020-12-22 普莱希科公司 Compounds and methods for IDO and TDO modulation, and indications thereof
CN108752272B (en) * 2018-06-19 2021-02-19 西安交通大学 8-aminoquinoline amide derivative, preparation method, application and fluorescence analysis method thereof
EP3962903A1 (en) 2019-05-01 2022-03-09 Boehringer Ingelheim International GmbH (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
CN111053761B (en) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 Bisphosphonic acid medicine for inhalation, preparation method thereof and application thereof in chronic obstructive pulmonary disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
JP2010208947A (en) * 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd Quinolone derivative

Also Published As

Publication number Publication date
SG175877A1 (en) 2011-12-29
WO2010129467A8 (en) 2010-12-16
CA2761009A1 (en) 2010-11-11
IL216107A0 (en) 2012-01-31
WO2010129467A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
MX2011011735A (en) Compounds and methods for inhibition of renin, and indications therefor.
WO2012037155A3 (en) Tyrosine kinase inhibitors
SG190819A1 (en) Nampt and rock inhibitors
MX2012000709A (en) Pyrrolopyridine inhibitors of kinases.
EA201200917A1 (en) PROCARAXES OF PLASMA KALLIKREIN INHIBITORS
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
UA104885C2 (en) Isothiazolyloxyphenyl amidines and use thereof as fungicides
PH12013501772A1 (en) Inhibitors of e1 activating enzyme
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
UA115983C2 (en) Dna-pk inhibitors
EP2595482A4 (en) Aldosterone synthase inhibitors
MX2012011380A (en) Multisubstituted aromatic compounds as inhibitors of thrombin.
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2019003089A (en) Microrna compounds and methods for modulating mir-21 activity.
MX353257B (en) Heterocyclic compounds useful as pdk1 inhibitors.
JO3450B1 (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
MY165728A (en) Selective glycosidase inhibitors and uses thereof
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2011011272A (en) Processes and intermediates.
MX2012004780A (en) Akt inhibitors.
AU2011326186A8 (en) Selective glycosidase inhibitors and uses thereof
MX2013002851A (en) Inhibitors of notum pectinacetylesterase and methods of their use.
MX348311B (en) Nampt inhibitors.
AU2013318309A8 (en) Methods for treating hepatitis C
WO2011083482A3 (en) Method for treatment of psoriasis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal